Elaine Jones, executive director of Pfizer Venture Investments, will be an observer to Neuronetics' board and said: "Pfizer has had a longstanding interest in treating depression."
Pfizer Venture Investments, the corporate venturing unit of US-listed drugs company Pfizer, has co-led as a new investor the $30m series E round for Neuronetics, which treats depression.
Venture capital firm Polaris Venture Partners also co-led the E round, and was joined by peers Investor Growth Capital, New Leaf Venture Partners, Three Arch Partners, Interwest Partners, Onset Ventures and Quaker BioVentures, while Accuitive Medical Ventures (which had been launched in 2004 out of medical device incubator The Innovation Factory)…
